

Supporting Information

Emphasis on pharmaceutically acceptable solvates: Linking Solubility with Iso-structurality for Better Drug Design

Ramesh Reddy Mudda,^a Ramesh Devarapalli,^a Manjunath Bollineni,^a Arijit Das,^a Ramanaiah Chennuru.^{a*}

^aCentre of Excellence Polymorphism, Research and Development, Integrated Product Development (IPD), Cipla Ltd., Bangalore, India.

*Corresponding authors

Dr. Ramanaiah Chennuru

Centre of Excellence Polymorphism, Research and Development, Integrated Product Development (IPD), Cipla Ltd., Virgonagar, Bangalore-560 049, Karnataka, India

Email: Ramanaiah.Chennuru@Cipla.com

Contact No: +91-80-46912332. Fax No: +91-80-28472795.




Figure S1: Powder X-ray Diffraction pattern of AM-I.




Figure S2. Overlay of DSC, TGA thermograms and TGA 1st derivative curve of AM-I.




Figure S3: Powder X-ray Diffraction pattern of AM-II.




Figure S4. Overlay of DSC, TGA thermograms and TGA 1st derivative curve of AM-II.




Figure S5: ^1H NMR overlay of AM-I and AM-II.

AM-I ^1H -NMR (500 MHz, d_6 -DMSO) δ : 1.67 (s, 1 H), 1.95 - 2.06 (m, 3 H), 2.08 - 2.50 (m, 3 H), 3.55-3.63 (m, 1 H), 3.83 (t, J = 7 Hz, 1 H), 5.49 - 5.77 (m, 1 H), 6.14 (s, 2 H), 7.14 - 7.20 (m, 2 H), 7.37 (s, 1 H), 7.74 - 7.77 (m, 2 H), 7.87 (t, J = 7.5 Hz, 1 H), 7.93 - 7.97 (m, 1 H), 8.21 (d, J = 8 Hz, 2 H), 8.22 (d, J = 8.4 Hz, 1 H), 8.41 (d, J = 4.7 Hz, 1 H).

AM-II ^1H -NMR (500 MHz, d_6 -DMSO) δ : 1.10 (t, J = 7 Hz, 1 H), 1.67 (s, 1 H), 1.98-2.04 (m, 3 H), 2.12 - 2.50 (m, 3 H), 3.33 (q, J = 7 Hz, 2 H), 3.41-3.63 (m, 1 H), 3.83 (t, J = 7 Hz, 1 H), 5.49 - 5.77 (m, 1 H), 6.14 (s, 2 H), 7.14 - 7.20 (m, 2 H), 7.35 (s, 1 H), 7.74 - 7.77 (m, 2 H), 7.85 (t, J = 7.5 Hz, 1 H), 7.93 - 7.97 (m, 1 H), 8.20 (d, J = 8 Hz, 2 H), 8.22 (d, J = 8.4 Hz, 1 H), 8.40 (d, J = 4.7 Hz, 1 H).




Figure S6: FTIR spectra of AM-I (a) 625 to 4000cm⁻¹ (b) 625 to 2000 cm⁻¹.




Figure S7: FTIR spectra of AM-II (a) 625 to 4000cm⁻¹ (b) 625 to 2000 cm⁻¹.




Figure S8: Microscopic image of AM-I single crystals.




Figure S9: Microscopic image of AM-II single crystals.

Table S1: Experimental polymorph screening details of Acalabrutinib maleate.

Slurry crystallization				
S. No.	Input form	Solvent	Temp. (°C)	XRD Result
1	Amorphous	2-Butanol	25-30	AM-I
2	Amorphous	Acetone	25-30	AM-I
3	Amorphous	Acetone + Water (1:1)	25-30	AM-I
4	Amorphous	Acetone + Water (9:1)	25-30	AM-I
5	Amorphous	Acetonitrile	25-30	AM-I
6	Amorphous	Acetonitrile	45-50	AM-I
7	Amorphous	Acetonitrile + Water (1:1)	25-30	AM-I
8	Amorphous	Acetonitrile + Water (9:1)	25-30	AM-I
9	Amorphous	Ethanol	25-30	AM-I and extra peaks observed
10	Amorphous	Ethanol	0-5	AM-I
11	Amorphous	Ethanol	65-70	AM-I and extra peaks observed
12	Amorphous	Ethanol + Isopropanol (1:1)	0-5	AM-I
13	Amorphous	Ethanol + Acetone (1:1)	25-30	AM-I
14	Amorphous	Ethanol + Water (1:1)	25-30	AM-I
15	Amorphous	Ethanol + Water (9:1)	25-30	AM-I
16	Amorphous	Ethyl acetate	25-30	AM-I
17	Amorphous	Isopropyl acetate	25-30	AM-I
18	Amorphous	n-Butyl acetate	25-30	AM-I

19	Amorphous	Heptane	25-30	AM-I
20	Amorphous	Isopropanol	25-30	AM-I
21	Amorphous	Isopropanol + Water (1:1)	25-30	AM-I
22	Amorphous	Isopropanol + Water (9:1)	25-30	AM-I
23	Amorphous	Methanol	50-55	AM-I
24	Amorphous	Methanol + Water (1:1)	25-30	AM-I
25	Amorphous	Methanol + Water (9:1)	25-30	AM-I
26	Amorphous	Nitromethane + Water (1:1)	25-30	AM-I
27	Amorphous	Nitromethane + Water (9:1)	25-30	AM-I
28	Amorphous	Toluene	25-30	AM-I
29	Amorphous	Water	25-30	AM-I
30	Amorphous	Water	70-75	AM-I
31	AM-I	Dimethyl acetamide	25-30	AM-I
32	AM-I	Dimethyl acetamide	70-75	AM-I
33	AM-I	Dimethyl formamide	25-30	AM-I
34	AM-I	Dimethyl formamide	70-75	AM-I
35	AM-I	Dimethyl sulfoxide	25-30	AM-I
36	AM-I	Dimethyl sulfoxide	70-75	AM-I
37	AM-I	Ethanol + Water (9.5:0.5)	55-60	AM-II
38	AM-I	Methanol + Water (9.5:0.5)	-5 - -10	AM-I
39	AM-I	Toluene	50-55	AM-I
40	AM-I	Toluene	95-100	AM-I
41	AM-I	Xylene	50-55	AM-I
42	AM-I	Water	50-55	AM-I
43	AM-I	Heptane	50-55	AM-I
44	AM-I	Methyl tertiary butyl ether	40-45	AM-I
45	AM-I	Methyl isobutyl ketone	25-30	AM-I
46	AM-I	Methyl isobutyl ketone	50-55	AM-I
47	AM-I	Di isopropyl ether	25-30	AM-I
48	AM-I	Di isopropyl ether	45-50	AM-I
49	AM-I	2-Methyl tetrahydrofuran	55-60	AM-I
50	AM-I	Methyl isopropyl ketone	45-50	AM-I
51	AM-I	Dimethyl carbonate	45-50	AM-I
52	AM-I	Dimethyl carbonate	80-85	AM-I
Recrystallization				
S. No.	Input Form	Solvent	Temp. (°C)	XRD Result
1	Amorphous	Benzyl alcohol	0-5	AM-I
2	AM-I	Trifluoro ethanol	-10 - -15	AM-I
3	AM-I	Acetic acid	25-30	AM-I
4	Amorphous	Acetonitrile	-10 - -15	AM-I

5	AM-I	Aniline	25-30	AM-I	
6	AM-I	Benzyl alcohol/Methanol	25-30	AM-I	
7	Amorphous	Chloroform	-10 - -15	AM-I	
8	Amorphous	Dichloromethane	-10 - -15	AM-I	
9	Amorphous	Dichloromethane/Acetone	-10 - -15	AM-I	
10	AM-I	N, N-Dimethylacetamide	0-5	AM-I	
11	AM-I	Dimethyl sulfoxide	25-30	AM-I	
12	Amorphous	1,4-Dioxane	25-30	AM-I	
13	Amorphous	2-Ethoxyethanol	-10 - -15	AM-I	
14	Amorphous	Methanol	-10 - -15	AM-I	
15	Amorphous	Methanol/Water	-10 - -15	AM-I	
16	AM-I	N-Methylpyrrolidone	25-30	AM-I	
17	Amorphous	Propylene glycol	-10 - -15	AM-I	
18	Amorphous	Tetrahydrofuran/Methanol	-10 - -15	AM-I	
19	Amorphous	Tetrahydrofuran/Acetone	-10 - -15	AM-I	
20	Amorphous	Tetrahydrofuran	-10 - -15	AM-I	
Anti-solvent addition crystallization					
S. No.	Input Form	Solvent	Antisolvent	Temp. (°C)	XRD Result
1	Amorphous	Trifluoro ethanol	Isopropyl acetate	25-30	AM-I
2	AM-I	Acetic acid	Methyl tertiary butyl ether	0-5	AM-I
3	AM-I	Acetic acid	Heptane	0-5	AM-I
4	AM-I	Acetic acid	Acetone	25-30	AM-I
5	AM-I	Acetic acid	Methyl isobutyl ketone	25	AM-I
6	Amorphous	Acetonitrile	Methyl tertiary butyl ether	25-30	AM-I
7	Amorphous	Acetonitrile	Isopropyl acetate	0-5	AM-I
8	Amorphous	Acetonitrile	Heptane	25-30	AM-I
9	AM-I	Aniline	Di isopropyl ether	0-5	AM-I
10	AM-I	Aniline	Heptane	0-5	AM-I
11	Amorphous	Benzyl alcohol	Isopropyl acetate	25-30	AM-I
12	AM-I	Benzyl alcohol	Methyl tertiary butyl ether	25-30	AM-I
13	AM-I	Benzyl alcohol	Ethyl acetate	0-5	AM-I
14	AM-I	Benzyl alcohol	Heptane	0-5	AM-I
15	Amorphous	Chloroform	Methyl tertiary butyl ether	0-5	AM-I
16	Amorphous	Chloroform	Toluene	25-30	AM-I
17	Amorphous	Chloroform	Heptane	0-5	AM-I
18	Amorphous	Dichloromethane	Di isopropyl ether	0-5	AM-I
19	AM-I	Dichloromethane	Methyl isobutyl ketone	23-75	Solid not isolated
20	Amorphous	Dichloromethane	Heptane	25-30	AM-I
21	AM-I	N, N-Dimethylacetamide	Methyl tertiary butyl ether	0-5	AM-I

22	AM-I	N, N-Dimethylacetamide	Heptane	25-30	AM-I
23	AM-I	N, N-Dimethylformamide	Methyl tertiary butyl ether	25-30	AM-I
24	AM-I	N, N-Dimethyl formamide	Heptane	0-5	AM-I
25	AM-I	Dimethyl sulfoxide	Di isopropyl ether	0-5	AM-I
26	AM-I	Dimethyl sulfoxide	n-propyl acetate	25-30	AM-I
27	AM-I	Dimethyl sulfoxide	Hexane	0-5	AM-I
28	Amorphous	1,4-Dioxane	Methyl tertiary butyl ether	0-5	AM-I
29	Amorphous	1,4-Dioxane	Heptane	25-30	AM-I
30	Amorphous	2-Ethoxyethanol	Methyl tertiary butyl ether	25-30	AM-I
31	Amorphous	2-Ethoxyethanol	Pentane	0-5	AM-I
32	AM-I	Formic acid	Methyl isobutyl ketone	70-75	AM-I and extra peak
33	AM-I	Formic acid	Acetone + Methyl isobutyl ketone	50-55	AM-I
34	Amorphous	Methanol	Methyl tertiary butyl ether	0-5	AM-I
35	Amorphous	Methanol	2-Butanol + Water	0-5	AM-I
36	Amorphous	Methanol	Water	25-30	AM-I
37	Amorphous	Methanol	Ethyl acetate	0-5	AM-I
38	Amorphous	Methanol	Xylene	0-5	AM-I
39	AM-I	2-Methoxyethanol	Acetone	75°C	AM-I
40	AM-I	N-Methyl pyrrolidine	Water	75°C	AM-I
41	AM-I	N-Methyl pyrrolidine	Ethyl acetate	75°C	AM-I
42	AM-I	N-Methylpyrrolidone	Methyl tertiary butyl ether	0-5	AM-I
43	AM-I	N-Methylpyrrolidone	Heptane	0-5	AM-I
44	AM-I	Propylene glycol	Methyl tertiary butyl ether	25-30	AM-I
45	AM-I	Propylene glycol	Ethyl acetate	0-5	AM-I
46	AM-I	Propylene glycol	Heptane	0-5	AM-I
47	Amorphous	Tetrahydrofuran	Methyl tertiary butyl ether	0-5	AM-I
48	Amorphous	Tetrahydrofuran	Water	25-30	AM-I
49	Amorphous	Tetrahydrofuran	Xylene	0-5	AM-I
50	Amorphous	Tetrahydrofuran	Heptane	25-30	AM-I

Reactive crystallization

In the following mentioned experiments, Different polymorphs of Acalabrutinib base were used. Maleic acid was calculated (~1 to 1.1 mole equivalents) according to the input base quantity.

S. No.	Solvent	Antisolvent	Temperature (°C)	XRD Result
1	Water	NA	25-30	AM-I
2	Water	NA	70-75	AM-I

3	1,4-Dioxane + Ethanol (9.5:0.5)	NA	0-5	AM-I
4	1,4-Dioxane + Water (9.5:0.5)	NA	25-30	AM-I
5	1-Butanol	Methyl tertiary butyl ether	25-30	AM-I
6	2-Butanol	Methyl tertiary butyl ether	25-30	AM-I
7	2-Ethoxy ethanol	Methyl tertiary butyl ether + Heptane (1:1)	-5 - -10	AM-I
8	2-Methyl tetrahydrofuran	NA	25-30	AM-I
9	2-Pentanol	Methyl tertiary butyl ether	25-30	AM-I
10	Acetic acid	Water	0-5	Solid not isolated
11	Acetone	Heptane	45-50	AM-I
12	Acetone	Heptane	0-5	AM-I
13	Acetone	Water	35-40	AM-I
14	Acetone	Water	25-30	AM-I
15	Acetone	Water	0-5	AM-I
16	Acetonitrile	Methyl tertiary butyl ether	45-50	AM-I
17	Acetonitrile	DIPE	-5 - -10	AM-I
18	Acetonitrile	DIPE	45-50	AM-I
19	Anisole	NA	25-30	AM-I
20	Cyclopentyl methyl ether	NA	25-30	AM-I
21	Cyclopentyl methyl ether + Ethanol (1:1)	NA	25-30	AM-I
22	Cyclopentyl methyl ether + Ethanol (1:1)	NA	60-65	AM-I
23	Dichloromethane	NA	0-5	AM-I
24	Dichloromethane	NA	25-30	AM-I
25	Diethyl carbonate	NA	25-30	AM-I
26	Diethyl carbonate	NA	55-60	AM-I
27	Dimethoxy methane	NA	25-30	AM-I
28	Di isopropyl ether	NA	25-30	AM-I
29	Dimethyl formamide + Water (9:1)	Methyl tertiary butyl ether	0-5	AM-I
30	Dimethyl formamide + Water (9:1)	Methyl tertiary butyl ether	50-55	AM-I

31	Dimethyl sulfoxide	Ethyl acetate + Methyl tertiary butyl ether (1:1)	0-5	AM-I
32	Dimethyl sulfoxide + Water (9:1)	NA	25-30	AM-I
33	Ethanol	NA	50-55	AM-II
34	Ethanol + Water (9:1)	NA	0-5	AM-II
35	Ethanol + Water (9:1)	NA	50-55	AM-II
36	Ethyl acetate	Heptane	25-50	AM-I
37	Formic acid	Water	0-5	Solid not isolated
38	Formic acid	Water	25-45	AM-I
39	Heptane	NA	25-50	Acalabrutinib Base
40	Isopropanol	NA	0-5	AM-I
41	Isopropanol	NA	50-55	AM-I
42	Isopropanol	Heptane	35-40	AM-I
43	Isopropanol	Hexane	35-40	AM-I
44	Isopropyl acetate + Isopropanol (1:1)	NA	25-30	AM-I
45	Isobutyl acetate + Isopropanol (1:2)	NA	25-30	AM-I
46	Isopropyl acetate	NA	25-30	AM-I
47	Dichloromethane	Heptane	0-5	Amorphous
48	Dichloromethane	Heptane	25-30	AM-I
49	Dichloromethane	Tetrahydrofuran	25-30	AM-I
50	Methanol	NA	0-5	AM-I
51	Methanol	NA	45-50	AM-I
52	Methanol + Water (9:1)	NA	0-5	AM-I
53	Methanol + Water (9:1)	NA	50-55	AM-I
54	Methyl isobutyl ketone	Heptane	25-30	AM-I
55	Methyl isobutyl ketone	Heptane	40-45	AM-I
56	Methyl tertiary butyl ether	NA	25-30	AM-I
57	Methyl tertiary butyl ether	NA	50-55	AM-I
59	Water	NA	70-75	AM-I
60	Water	NA	25-30	AM-I

61	Nitromethane	NA	55-60	AM-I
62	Nitromethane	NA	25-30	AM-I
63	Propionitrile	NA	25-30	AM-I
64	Tertiary butyl alcohol	Methyl tertiary butyl ether	25-30	AM-I
65	Tetrahydrofuran	Heptane	0-5	Amorphous
66	Tetrahydrofuran	Heptane	40-45	Amorphous
67	Tetrahydrofuran	Water	25-30	AM-I
68	Tetrahydrofuran	Water	45-50	AM-I
69	Trifluoroethanol	Methyl tertiary butyl ether	0-5	AM-I
70	Trifluoroethanol	Methyl tertiary butyl ether	25-30	AM-I
71	Vinyl acetate + Ethanol (1:2)	NA	0-5	AM-I
72	Vinyl acetate + Ethanol (1:2)	NA	60-65	AM-I

Table S2. Crystallographic parameters of AM-I and AM-II.

Crystallographic parameters	Acalabrutinib maleate sesquihydrate (AM-I)	Acalabrutinib maleate hemiethanol hemihydrate (AM-II)
Chemical formula	$C_{60}H_{60}N_{14}O_{15}$	$C_{62}H_{62}N_{14}O_{14}$
Asymmetric unit	$2(C_{26}H_{24}N_7O_2), 2(C_4H_3O_4), 3(H_2O)$	$2(C_{26}H_{24}N_7O_2), 2(C_4H_3O_4), (C_2H_6O), (H_2O)$
Formula weight	1217.22	1227.26
Crystal system	Triclinic	Triclinic
Space group	<i>P</i> 1	<i>P</i> 1
<i>T</i> [K]	100.01(10)	100.00(10)
<i>a</i> [Å]	9.5583(5)	9.49588(14)
<i>b</i> [Å]	9.5900(5)	9.79722(17)
<i>c</i> [Å]	17.1147(5)	17.0733(2)
α [°]	78.722(3)	78.0108(13)
β [°]	79.352(3)	81.7049(12)
γ [°]	69.659(5)	70.9622(14)
<i>Z</i>	1	1
<i>Z'</i>	1	1
<i>V</i> [Å ³]	1430.89 (11)	1463.72 (4)

ρ_{calc} [g/cm ³]	1.413	1.392
Radiation	CuK α (λ = 1.54184)	CuK α (λ = 1.54184)
Absorption correction	multiscan	multiscan
Index ranges	-11 $\leq$ h $\leq$ 11 -11 $\leq$ k $\leq$ 11 -19 $\leq$ l $\leq$ 20	-10 $\leq$ h $\leq$ 11 -11 $\leq$ k $\leq$ 11 -20 $\leq$ l $\leq$ 20
Reflections collected	12710	25082
Independent reflns.	6679	8266
Data/restraints/parameters	6679/3/836	8266/3/821
R_1 [$I \geq 2\sigma(I)$]	0.0504	0.0429
wR_2 (all)	0.1330	0.1151
$\Delta\rho_{\text{max}}$ (e/Å ³)	0.26	0.31
$\Delta\rho_{\text{min}}$ (e/Å ³)	-0.41	-0.29
Goodness-of-fit on F^2	1.049	1.053
Instrument	XtaLAB Synergy, Dualflex, HyPix3000	XtaLAB Synergy, Dualflex, HyPix3000
CCDC No.	2274946	2274947




Figure S10: View of asymmetric unit of AM-I showing the atomic numbering and 50% probability displacement ellipsoids. C - bound H atoms omitted for clarity. For the disordered atoms O15 and C51, only major components are shown. The big letters A and B near the corresponding Acalabrutinib cations represent the molecule A and molecule B in the manuscript.




Figure S11: Comparison of experimental and calculated PXRD plots of AM-I.




Figure S12: View of asymmetric unit of AM-II showing the atomic numbering and 50% probability displacement ellipsoids. C - bound H atoms omitted for clarity.




Figure S13: Comparison of experimental and calculated PXRD plots of AM-II.

Table S3: Torsion angles ($^{\circ}$) that are majorly deviated in AM-I and AM-II.

Considered consecutive atoms	AM-I		AM-II	
	Molecule A	Molecule B	Molecule A	Molecule B
C6-N2-C3-N1	-167.1(4)	-174.5(4)	-160.9(2)	-175.5(3)
C3-N2-C6-C7	172.9(4)	176.5(4)	170.0(2)	175.6(2)
N3-C15-C19-N7	120.3(5)	128.6(5)	125.8(3)	119.7(3)
N4-C15-C19-N7	-58.0(6)	-49.5(6)	-53.4(3)	-54.6(4)
C9-C10-C13-N4	137.1(4)	139.9(4)	131.7(2)	136.1(3)

Table S4: Hydrogen bond parameters of AM-I and AM-II

Interaction	D–H/Å	H···A/Å	D···A/Å	∠D–H···A/°	Symmetry code
AM-I					
N5–H5···O6	0.86	1.88	2.733(4)	173	x, y, -1+z
O3–H3···O5	0.82	1.67	2.471(4)	164	x, y, z
N6–H6A···O5	0.86	1.97	2.794(4)	160	x, y, -1+z
N9–H9···O15A	0.86	2.33	3.090(9)	147	x, y, z
O9–H9B···O11	0.82	1.65	2.472(4)	174	x, y, z
N12–H12···O12	0.86	1.86	2.711(5)	170	x, y, z
N13–H13A···O11	0.86	2	2.808(4)	156	x, y, z
O13–H13D···O14	0.85	2.27	2.991(9)	142	x, y, z
O14–H14A···O6	0.85	2.43	3.163(7)	145	x, y, z
O15A–H15A···N8	0.85	2.09	2.804(10)	142	x, y, z
O15A–H15B···N1	0.85	2.11	2.930(12)	161	x, 1+y, z
C1–H1···O12	0.93	2.5	3.398(6)	162	x, y, -1+z
C5–H5A···O2	0.93	2.45	3.339(6)	161	x, y, -1+z
C26–H26B···N11	0.96	2.61	3.466(7)	148	x, 1+y, z
C29–H29···O8	0.93	2.35	3.164(5)	146	x, y, z
C31–H31···O6	0.93	2.45	3.378(7)	179	x, 1+y, z
C35–H35···O8	0.93	2.33	3.245(8)	169	x, 1+y, z
C48–H48···O4	0.93	2.47	3.392(6)	170	x, -1+y, z
C49–H49···O4	0.98	2.56	3.503(6)	162	x, -1+y, z
C52–H52B···N4	0.97	2.61	3.531(6)	158	x, y, z
C59–H59···O2	0.93	2.36	3.208(5)	151	x, 1+y, z
AM-II					
O3–H3···O5	0.84	1.61	2.453(3)	175	x, y, z
N5–H5···O12	0.88	1.87	2.747(3)	172	x, y, z
N6–H6A···O11	0.88	1.92	2.775(3)	163	x, y, z
O9–H9B···O11	0.84	1.63	2.466(3)	175	x, y, z
N12–H12A···O6	0.88	1.85	2.717(3)	168	x, y, 1+z
O13–H13···N1	0.84	2.02	2.817(3)	158	x, y, z
N13–H13A···O5	0.88	2.04	2.819(3)	146	x, y, 1+z
O14–H14A···O13	0.87	1.94	2.766(3)	158	x, y, z
O14–H14B···O12	0.87	2.16	2.989(3)	158	-1+x, y, z
C1–H1···O6	0.95	2.59	3.513(4)	164	x, -1+y, z

C5–H5A···O2	0.95	2.37	3.302(3)	167	x, y, -1+z
C9–H9···O5	0.95	2.59	3.517(3)	166	x, y, z
C18–H18···O4	0.95	2.57	3.505(4)	169	x, y, -1+z
C19–H19···O4	1	2.45	3.432(4)	168	x, y, -1+z
C29–H29···O2	0.95	2.32	3.165(3)	148	x, y, z
C35–H35···O8	0.95	2.32	3.251(4)	168	x, 1+y, 1+z
C48–H48···O10	0.95	2.43	3.370(3)	169	-1+x, -1+y, z
C49–H49···O10	1	2.48	3.460(3)	167	-1+x, -1+y, z
C52–H52B···N4	0.99	2.51	3.464(3)	162	x, y, z
C59–H59···O8	0.95	2.39	3.238(3)	148	x, y, -1+z




Figure S14: PXR D pattern overlay of solubility study residues in comparison with initial AM-II. In all the three pH conditions, AM-II has converted to AM-I. The characteristic peaks of AM-II are shown with dotted lines (green: novel peaks of AM-II; Red: Absent peaks of Am-I in AM-II) to clearly identify the transformation.




Figure S15: X-ray powder diffraction pattern overlay of initial, 1st, 3rd, and 6th month stability at 40°C/75%RH.




Figure S16: X-ray powder diffraction pattern overlay of initial, 1st, 3rd, and 6th month stability at 25°C/60%RH.




Figure S17: X-ray powder diffraction pattern overlay of initial, 1st, 3rd, and 6th month stability at 2-8 °C.




Figure S18: HPLC chromatogram of AM-II: Input material's HPLC chromatogram.

Table S5: Impurity details of AM-II: Input material used for stability study.

Peak No.	Ret. Time (min)	Peak Name	Area (%)	RRT
1	9.180	ACA PYRROLIDINE	0.003	0.257
2	19.644	UNKNOWN	0.006	0.550
3	22.439	UNKNOWN	0.031	0.629
4	23.911	ACA DIKETO	0.008	0.670
5	27.772	UNKNOWN	0.004	0.778
6	32.732	UNKNOWN	0.004	0.917
7	35.697	ACALABRUTINIB	99.872	N.A.
8	44.231	UNKNOWN	0.015	1.239
9	44.977	ACA DIBUTYNOYL	0.004	1.260
10	49.628	ACA OPEN CHAIN IMP	0.004	1.390
11	61.511	ACA DIPYRROLIDINONE	0.031	1.723

12	63.399	UNKNOWN	0.003	1.776
13	64.316	UNKNOWN	0.003	1.802
14	72.337	UNKNOWN	0.002	2.026
15	73.916	ACA DIMER	0.006	2.071
16	78.588	UNKNOWN	0.004	2.202
Total:			100	

Summary	
Total Known Imp	0.060 %
Total Unknown Imp	0.075 %
Total Imp	0.135 %




Figure S19: HPLC chromatogram of AM-II: Stability interval - 6 months at 40 °C/75%RH.

Table S6: Impurity details of AM-II: Stability interval - 6 months at 40 °C/75%RH.

Peak No.	Ret. Time (min)	Peak Name	Area (%)	RRT
1	9.233	ACA PYRROLIDINE	0.003	0.259
2	19.729	UNKNOWN	0.007	0.553
3	22.513	UNKNOWN	0.030	0.631
4	23.985	ACA DIKETO	0.005	0.673
5	27.665	UNKNOWN	0.002	0.776
6	32.785	UNKNOWN	0.005	0.920
7	35.654	ACALABRUTINIB	99.856	N.A.
8	44.252	UNKNOWN	0.015	1.241
9	45.030	ACA DIBUTYNOYL	0.004	1.263
10	49.596	ACA OPEN CHAIN IMP	0.003	1.391
11	61.510	ACA DIPYRROLIDINONE	0.030	1.725
12	63.420	UNKNOWN	0.003	1.779
13	64.305	UNKNOWN	0.003	1.804
14	65.265	UNKNOWN	0.001	1.830
15	69.788	UNKNOWN	0.001	1.957
16	72.348	UNKNOWN	0.003	2.029
17	73.916	ACA DIMER	0.006	2.073
18	77.009	UNKNOWN	0.020	2.160

19	78.620	UNKNOWN	0.003	2.204
Total:			100	

Summary	
Total Known Imp	0.060 %
Total Unknown Imp	0.092 %
Total Imp	0.152 %





Figure S20: HPLC chromatogram of AM-II: Stability interval - 6 months at 25 °C/60%RH.

Table S7: Impurity details of AM-II: Stability interval - 6 months at 25 °C/60%RH.

Peak No.	Ret. Time (min)	Peak Name	Area (%)	RRT
1	9.223	ACA PYRROLIDINE	0.003	0.259
2	19.687	UNKNOWN	0.007	0.552
3	22.492	UNKNOWN	0.030	0.631
4	24.028	ACA DIKETO	0.008	0.674
5	32.796	UNKNOWN	0.006	0.920
6	35.655	ACALABRUTINIB	99.874	N.A.
7	44.242	UNKNOWN	0.015	1.241
8	45.084	ACA DIBUTYNOYL	0.004	1.264
9	49.586	ACA OPEN CHAIN IMP	0.004	1.391
10	61.500	ACA DIPYRROLIDINONE	0.029	1.725
11	63.410	UNKNOWN	0.002	1.778
12	64.327	UNKNOWN	0.003	1.804
13	65.234	UNKNOWN	0.002	1.830
14	72.327	UNKNOWN	0.002	2.029
15	73.916	ACA DIMER	0.006	2.073
16	78.588	UNKNOWN	0.003	2.204
Total:			100	

Summary	
Total Known Imp	0.065 %
Total Unknown Imp	0.070 %

Total Imp	0.135 %
-----------	---------



Fi

Figure S21: HPLC chromatogram of AM-II: Stability interval - 6 months at 2-8 °C.

Table S8: Impurity details of AM-II: Stability interval - 6 months at 2-8 °C.

Peak No.	Ret. Time (min)	Peak Name	Area (%)	RRT
1	9.262	ACA PYRROLIDINE	0.004	0.259
2	19.768	UNKNOWN	0.006	0.553
3	22.563	UNKNOWN	0.031	0.631
4	24.056	ACA DIKETO	0.008	0.673
5	32.878	UNKNOWN	0.005	0.920
6	35.747	ACALABRUTINIB	99.866	N.A.
7	44.323	UNKNOWN	0.017	1.240
8	45.059	ACA DIBUTYNOYL	0.007	1.260
9	49.720	ACA OPEN CHAIN IMP	0.003	1.391
10	61.582	ACA DIPYRROLIDINONE	0.032	1.723
11	63.512	UNKNOWN	0.003	1.777
12	64.440	UNKNOWN	0.003	1.803
13	72.387	UNKNOWN	0.003	2.025
14	73.923	ACA DIMER	0.007	2.068
15	78.606	UNKNOWN	0.005	2.199
Total:			100	

Summary	
Total Known Imp	0.070 %
Total Unknown Imp	0.073 %
Total Imp	0.143 %